Published

Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE): Results of a randomized active placebo-controlled trial

No abstract is available for this record.

Open source BibTeX RIS

Bibliographic context

Journal: Neuroscience Applied
Date: 2025-12-31
Source: OpenAlex
DOI: 10.1016/j.nsa.2025.105779
PubMed: Unavailable

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE): Results of a randomized active placebo-controlled trial2025-12-31

Related papers

Pilot study of psilocybin in patients with post-treatment lyme diseaseScientific Reports · 2026-02-24 The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysisBMC Psychology · 2026-01-01 Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidencePsychedelics. · 2025-10-27 Psilocybin and Chronic Pain: A New Perspective for Future Pain Therapists?Medical Sciences · 2025-11-19 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-18 The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.ClinicalTrials.gov · 2026-05-07 Psilocybin may help cancer patients with depression and anxiety for yearsAccess Science · 2019-12-31 The Utility of Psilocybin in Managing Anxiety and Depression in Cancer PatientsBiochemistry and Molecular Biology Education · 2018-07-31